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Summary
Background In estimating the global burden of cancer, adolescents and young adults with cancer are often overlooked, 
despite being a distinct subgroup with unique epidemiology, clinical care needs, and societal impact. Comprehensive 
estimates of the global cancer burden in adolescents and young adults (aged 15–39 years) are lacking. To address this 
gap, we analysed results from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, with a 
focus on the outcome of disability-adjusted life-years (DALYs), to inform global cancer control measures in adolescents 
and young adults.
Methods Using the GBD 2019 methodology, international mortality data were collected from vital registration systems, 
verbal autopsies, and population-based cancer registry inputs modelled with mortality-to-incidence ratios (MIRs). 
Incidence was computed with mortality estimates and corresponding MIRs. Prevalence estimates were calculated using 
modelled survival and multiplied by disability weights to obtain years lived with disability (YLDs). Years of life lost (YLLs) 
were calculated as age-specific cancer deaths multiplied by the standard life expectancy at the age of death. The main 
outcome was DALYs (the sum of YLLs and YLDs). Estimates were presented globally and by Socio-demographic Index 
(SDI) quintiles (countries ranked and divided into five equal SDI groups), and all estimates were presented with 
corresponding 95% uncertainty intervals (UIs). For this analysis, we used the age range of 15–39 years to define 
adolescents and young adults.
Findings There were 1·19 million (95% UI 1·11–1·28) incident cancer cases and 396 000 (370 000–425 000) deaths due 
to cancer among people aged 15–39 years worldwide in 2019. The highest age-standardised incidence rates occurred 
in high SDI (59·6 [54·5–65·7] per 100 000 person-years) and high-middle SDI countries (53·2 [48·8–57·9] per 
100 000 person-years), while the highest age-standardised mortality rates were in low-middle SDI (14·2 [12·9–15·6] 
per 100 000 person-years) and middle SDI (13·6 [12·6–14·8] per 100 000 person-years) countries. In 2019, adolescent 
and young adult cancers contributed 23·5 million (21·9–25·2) DALYs to the global burden of disease, of which 2·7% 
(1·9–3·6) came from YLDs and 97·3% (96·4–98·1) from YLLs. Cancer was the fourth leading cause of death and 
tenth leading cause of DALYs in adolescents and young adults globally.
Interpretation Adolescent and young adult cancers contributed substantially to the overall adolescent and young adult 
disease burden globally in 2019. These results provide new insights into the distribution and magnitude of the 
adolescent and young adult cancer burden around the world. With notable differences observed across SDI settings, 
these estimates can inform global and country-level cancer control efforts.
Funding Bill & Melinda Gates Foundation, American Lebanese Syrian Associated Charities, St Baldrick’s Foundation, 
and the National Cancer Institute.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Adolescents and young adults represent a heterogenous 
population consisting of individuals aged 15–39 years.1–3 
This formative time in life is unique, with several 
physical, emotional, and psychosocial changes, and 
with individuals potentially beginning or advancing 
their careers, higher education, relationships, and 
having children. The definitions and cutoffs of the age 
range for adolescents and young adults vary, but this 
age group is generally described as a subpopulation 
that is in transition between childhood and older 
adulthood.1
Adolescents and young adults develop cancers com­
monly found and treated in the paediatric population as 
well as the more common carcinomas seen in adults.4,5 
Additionally, some cancers are more prevalent in this age 
group than in younger or older individuals, such as 
Hodgkin lymphoma and gonadal germ cell tumours.6,7 
As a consequence, from a health­care delivery perspective, 
adolescent and young adult patients with cancer might 
struggle to find care that is optimal for both their cancer 
type and their age­related treatment needs.1 Additionally, 
adolescent and young adult patients often face social and 
financial challenges, which might result in inequities 
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in access to appropriate care, timely diagnosis, and 
treatment.1,3,8 Although adolescents and young adults 
have not seen the same improvements in cancer survival 
as younger and older cohorts for certain cancers, 
including acute myeloid leukaemia and soft tissue 
sarcomas,9 this population has not historically been a 
major focus of cancer control programmes and research 
development.10 Instead, based on historical precedent, 
adolescents and young adults are often grouped with 
adult patients in clinical care and clinical trials, and, as a 
consequence, comprehensive assessments of the cancer 
burden and epidemiological patterns in this age group 
are largely unknown or unreported in many settings.1
Previous studies have reported on global cancer 
incidence and mortality patterns of adolescents and 
young adults.4,5,11 One study used incidence and mortality 
estimates from GLOBOCAN 2012 for individuals aged 
20–39 years, another reported incidence and mortality 
estimates from GLOBOCAN 2018 for individuals aged 
15–39 years, and a third study reported international 
cancer incidence trends in individuals aged 15–39 years 
using data from the Cancer Incidence in Five Continents 
series, a publication comprising data from a subset of 
countries around the world with high­quality population­
based cancer registries.4,5,11 However, global differences in 
measures that incorporate both morbidity and mortality 
due to adolescent and young adult cancers remain unex­
plored. Consideration of more comprehensive disease 
burden metrics is especially relevant in adolescents and 
young adults, whose disease burden might put a strain on 
their evolving careers and families.1,12
The Global Burden of Diseases, Injuries, and Risk 
Factors Study (GBD) is the only global disease burden 
estimation framework that provides estimates of disability­
adjusted life­years (DALYs) for cancer as a metric to 
complement incidence and mortality data. DALYs are a 
key measure of disease burden that include both fatal and 
non­fatal impacts of disease, and are used in the 
Research in context
Evidence before this study
Adolescents and young adults with cancer represent a 
transition population within the cancer continuum between 
children and older adults. As adolescents and young adults 
with cancer are treated by a variety of specialists, their unique 
epidemiology and clinical care needs are often overlooked. 
Although improvements in survival for children and adults 
with cancer are reported in high-income countries, less 
incremental progress has been observed among adolescents 
and young adults. Added complexities of cancer in this age 
group include the potential impact of a cancer diagnosis on 
starting or caring for their families and careers, access to care, 
diagnostic delays, and abandonment of therapy—issues that 
exist globally. Previous work assessing the global burden of 
adolescent and young adult cancer has focused on incidence 
and mortality, and has occasionally used a more restrictive age 
range than presented in this study. International adolescent 
and young adult cancer incidence patterns across time have 
been reported with data from Cancer Incidence in 
Five Continents reports, and national-level estimates have 
been reported from select, primarily high-income, countries. 
These publications have begun to raise awareness of 
adolescents and young adults as a distinctive population 
within the oncology community globally. However, to our 
knowledge, no previous publication has incorporated the 
impact of morbidity or done a comparative analysis of cancer 
within the broader context of the adolescent and young adult 
disease burden. We searched PubMed for English-language 
research articles describing the global burden of adolescent and 
young adult cancers between Jan 1, 2010, and Feb 1, 2021, 
using the terms “adolescent and young adult or adolescent or 
young adult or AYA” and “oncology or cancer or neoplasm or 
tumor or malignancy” and “global or worldwide or 
international” and “incidence or mortality or morbidity or 
burden or prevalence or survival”, and identified no additional 
comprehensive adolescent and young adult global cancer 
estimate reports.
Added value of this study
We share for the first time, the formal global analysis of the 
cancer burden in individuals aged 15–39 years in 2019, using 
disability-adjusted life-years (DALYs) estimated by the Global 
Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019.
GBD 2019 is a valuable global health resource used to inform 
government health policy decisions around the world when 
comprehensive data might be absent. The global burden of 
cancer in terms of mortality and DALYs is substantial in the 
adolescent and young adult population. The global distribution 
of the adolescent and young adult cancer burden is unique, 
reflecting the shift from cancers that primarily affect children 
(eg, acute lymphoblastic leukaemia) to those that primarily 
affect adults (eg, carcinomas), and including cancers that occur 
most often in adolescents and young adults (eg, testicular 
cancers). Although high Socio-demographic Index (SDI) 
countries had the highest age-standardised incidence rates, 
they also had the lowest age-standardised mortality rates when 
compared to non-high SDI (low, low-middle, middle, 
and high-middle SDI) countries.
Implications of all the available evidence
The relative burden of deaths and DALYs due to adolescent and 
young adult cancer is high globally, concentrated primarily in 
non-high SDI settings. These estimates are crucial for 
comparing the burden of cancer to other causes of deaths and 
DALYs in adolescents and young adults and might be used to 
inform health policy and resource allocation priorities. Focus on 
adolescents and young adults as a distinct cancer population in 
the development of cancer control programmes is crucial to 
improving outcomes.
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development of national and global health policy.13 GBD 
estimates disease burden for more than 300 diseases and 
injuries, allowing for comparative analyses with other 
causes of morbidity and mortality in adolescents and 
young adults. To our knowledge, no formal GBD analysis 
has previously been done of the global burden of cancer in 
the adolescent and young adult population. In this study, 
we aimed to analyse and report adolescent and young 
adult cancer burden estimates, using the most 
encompassing definition of adolescents and young adults 
(ie, individuals aged 15–39 years),2,3 with a focused analysis 
on DALY estimates. DALYs represent an important 
comprehensive assessment of cancer burden in this 
distinctive population, adding to existing estimates of 
disease burden with more classic measures, and are 
crucial to informing cancer control strategies that address 
health disparities and inequities in this population.
Methods
GBD study overview
GBD was established to provide global disease burden 
metrics that are comprehensive and comparable over 
time. Estimates produced include incidence, prevalence, 
mortality, years of life lost (YLLs), years lived with 
disability (YLDs), and DALYs, measures that can each be 
used to describe different aspects of the adolescent and 
young adult cancer burden. Estimates are generated for 
each disease and injury and are reported by age group, 
sex, location, and year. Each GBD iteration replaces the 
previous round of GBD estimates for the entire estimated 
time series, so that updates to data and methods in the 
new GBD round are applied consistently across time. 
The present analysis was based on GBD 2019 estimates.13,14 
GBD 2019 was done in accordance with the Guideline for 
Accurate and Transparent Health Estimates Reporting 
(appendix pp 5, 6).15 Data sources used in GBD 2019 are 
available online and are further outlined in the appendix 
(p 10). This manuscript was produced as part of the GBD 
Collaborator Network and in accordance with the GBD 
Protocol. Analyses were completed with Python 
(versions 3.6.2 and 3.6.7), Stata (version 13), and R 
(versions 3.5.0 and 3.4.1).
Definitions
Although the definition of the age range for adolescents 
and young adults varies, particularly in the upper age 
limit,12,16,17 we used the age range of 15–39 years in this 
study, since this is the most encompassing age range 
definition recommended in oncology, is endorsed by the 
US National Cancer Institute and the AYA Working Group 
of the European Society for Medical Oncology and the 
European Society for Paediatric Oncology,3 and allows for 
comparability with other studies on adolescent and young 
adult cancer.1 Individuals aged 15–39 years have also 
experienced the least progress in survival outcomes in 
most countries.11 Data for this age range are available 
online with the GBD Results Tool and for subsets of this 
age range with the GBD Compare data visualisation tool 
or GBD Results Tool. As there are differences in the 
preferred age range used to define adolescents and young 
adults around the world, results of the narrower age range 
of 15–29 years are presented in the appendix (pp 115–122).
All malignant cancer types, as defined in the tenth 
revision of the International Classification of Diseases, 
chapter II (Neoplasms),18 were categorised into 32 cancer 
groups in this analysis, called causes in GBD and this 
Article. Non­melanoma skin cancers were excluded, 
since they are not a major cause of mortality in this age 
range. The cause “other malignant neoplasms” in GBD 
includes estimates for cancers not included in any other 
GBD cancer cause, such as bone cancers and soft tissue 
sarcomas (see appendix p 11 for more details about 
cancer mapping). The adolescent and young adult age 
group was compared to children (aged 0–14 years) and 
older adults (aged ≥40 years) in specific analyses. The 
focus of this analysis was on global and regional 
estimates, although GBD 2019 also produces estimates at 
the national and, for select countries, subnational level. 
National and subnational estimates are available in the 
GBD Compare and GBD Results tools online. Select 
results are presented by quintiles of the Socio­
demographic Index (SDI; countries ranked and divided 
into five equal SDI groups), which is a composite 
measure of income per capita, total fertility rate (age 
<25 years), and average educational fulfilment (for those 
aged ≥15 years), and is a useful summary measure of a 
country’s overall social and economic development that 
allows for analyses of disease burden patterns across 
different resource contexts (appendix p 56).14 All cancer 
rates were reported per 100 000 person­years. The GBD 
world population standard was used for the calculation of 
age­standardised rates (appendix p 56).
Estimation of cancer burden
The GBD cancer estimation process begins with a focus 
on mortality. Data sources include vital registration 
systems, verbal autopsies, and population­based cancer 
registration systems. Some cancer registries report 
incidence only; therefore, mortality­to­incidence ratios 
(MIRs) were used to convert cancer registry incidence 
data to estimates of mortality, increasing data availability 
in locations that might not have mortality data, but have 
active cancer registries. Using a spatiotemporal Gaussian 
process regression, MIRs were modelled for all combi­
nations of age, sex, year, and location with incidence 
data from cancer registries and mortality data from 
cancer registries or high­quality vital statistics registries 
(elaborated in the appendix pp 25, 26).13 Estimates of 
mortality obtained with MIRs were combined with vital 
registration and verbal autopsy mortality data and used as 
inputs in cancer type and sex­specific Cause of Death 
Ensemble models (CODEm).19 The CODEm methodology 
uses all available mortality data to select the optimal 
model or models on the basis of out­of­sample predictive 
See Online for appendix
For the data sources used in 
GBD 2019 see http://ghdx.
healthdata.org/gbd-2019
For the GBD Results Tool see 
http://ghdx.healthdata.org/ 
gbd-results-tool
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validity (appendix p 28). Cause­specific mortality esti­
mates were then scaled to independently modelled all­
cause mortality with CoDCorrect to ensure consistency.13
Incidence estimates were obtained by dividing the 
mortality estimates by the corresponding MIR for each 
cancer type. Survival estimates based on MIRs were used 
to model 10­year prevalence for each cancer cause 
(appendix pp 50, 51). Prevalence for each cancer cause 
was divided into distinct phases of cancer treatment to 




DALY rate per 




incidence rate per 




mortality rate per 
100 000 (95% UI)
Global 23 500 (21 900–25 200) 782·2 (730·8–838·1) 1190 (1110–1280) 39·7 (36·9–42·6) 396 (370–425) 13·2 (12·3–14·1)
SDI quintiles
High SDI quintile 2020 (1940–2110) 564·3 (542·8–590·1) 213 (195–235) 59·6 (54·5–65·7) 33·4 (32·2–34·7) 9·2 (8·9–9·6)
High-middle SDI quintile 4520 (4200–4840) 801·4 (745·8–857·8) 302 (277–329) 53·2 (48·8–57·9) 76·6 (71·1–82·2) 13·4 (12·4–14·3)
Middle SDI quintile 7780 (7190–8410) 810·1 (748·4–876·6) 369 (339–401) 38·3 (35·1–41·6) 132 (122–143) 13·6 (12·6–14·8)
Low-middle SDI quintile 5970 (5420–6530) 836·7 (760·1–915·5) 209 (188–229) 29·4 (26·5–32·2) 101 (91·4–110) 14·2 (12·9–15·6)
Low SDI quintile 3190 (2770–3630) 781·1 (678·2–890·0) 101 (86·3–115) 25·0 (21·4–28·7) 53·5 (46·5–60·9) 13·3 (11·6–15·2)
Cancers
Breast cancer 2490 (2260–2720) 82·1 (74·4–89·8) 170 (154–186) 5·6 (5·1–6·1) 43·1 (39·1–47·3) 1·4 (1·3–1·6)
Brain and CNS cancer 1750 (1380–1940) 58·4 (46·2–64·9) 61·5 (48·2–69·1) 2·1 (1·6–2·3) 29·1 (23·0–32·3) 1·0 (0·8–1·1)
Colon and rectum cancer 1630 (1510–1760) 53·9 (49·9–58·1) 76·1 (70·2–82·9) 2·5 (2·3–2·7) 28·4 (26·2–30·5) 0·9 (0·9–1·0)
Stomach cancer 1570 (1450–1700) 52·0 (47·8–56·2) 49·0 (45·0–53·1) 1·6 (1·5–1·8) 27·9 (25·7–30·2) 0·9 (0·8–1·0)
Cervical cancer 1560 (1 320–1780) 51·4 (43·5–58·7) 119 (99·6–135) 3·9 (3·3–4·5) 27·2 (22·9–31·1) 0·9 (0·8–1·0)
Tracheal, bronchus, and lung cancer 1390 (1270–1510) 45·8 (42·0–50·0) 32·6 (29·7–35·5) 1·1 (1·0–1·2) 24·8 (22·7–27·0) 0·8 (0·7–0·9)
Non-Hodgkin lymphoma 1280 (1190–1380) 42·8 (39·8–46·4) 52·4 (47·0–58·7) 1·8 (1·6–2·0) 20·8 (19·3–22·6) 0·7 (0·6–0·8)
Liver cancer 1050 (938–1160) 34·6 (31·0–38·4) 25·4 (22·7–28·4) 0·8 (0·8–0·9) 18·6 (16·6–20·7) 0·6 (0·5–0·7)
Other leukaemia 949 (791–1080) 32·0 (26·6–36·4) 28·8 (23·8–32·8) 1·0 (0·8–1·1) 15·3 (12·7–17·4) 0·5 (0·4–0·6)
Acute lymphoid leukaemia 766 (634–844) 26·1 (21·7–28·8) 38·7 (32·2–43·2) 1·3 (1·1–1·5) 11·7 (9·64–12·9) 0·4 (0·3–0·4)
Acute myeloid leukaemia 748 (678–858) 25·2 (22·9–28·9) 20·2 (18·2–22·8) 0·7 (0·6–0·8) 12·2 (11·0–14·0) 0·4 (0·4–0·5)
Lip and oral cavity cancer 580 (520–644) 19·2 (17·2–21·3) 29·4 (26·3–32·7) 1·0 (0·9–1·1) 10·0 (9·00–11·1) 0·3 (0·3–0·4)
Ovarian cancer 529 (443–602) 17·6 (14·7–20·0) 35·8 (30·5–41·0) 1·2 (1·0–1·4) 8·90 (7·46–10·1) 0·3 (0·2–0·3)
Hodgkin lymphoma 508 (432–600) 17·1 (14·5–20·2) 33·4 (29·9–40·5) 1·1 (1·0–1·4) 8·09 (6·85–9·52) 0·3 (0·2–0·3)
Pancreatic cancer 421 (387–463) 13·9 (12·8–15·3) 9·40 (8·59–10·3) 0·3 (0·3–0·3) 7·61 (6·98–8·39) 0·3 (0·2–0·3)
Nasopharynx cancer 363 (334–394) 12·1 (11·1–13·1) 28·6 (25·3–32·3) 0·9 (0·8–1·1) 6·08 (5·60–6·65) 0·2 (0·2–0·2)
Testicular cancer 349 (319–383) 11·7 (10·6–12·8) 57·4 (51·6–65·1) 1·9 (1·7–2·2) 5·35 (4·92–5·84) 0·2 (0·2–0·2)
Oesophageal cancer 344 (308–382) 11·3 (10·1–12·6) 8·09 (7·27–8·97) 0·3 (0·2–0·3) 6·21 (5·57–6·90) 0·2 (0·2–0·2)
Chronic myeloid leukaemia 295 (261–335) 9·8 (8·7–11·2) 9·20 (8·34–10·2) 0·3 (0·3–0·3) 4·96 (4·39–5·62) 0·2 (0·1–0·2)
Malignant skin melanoma 259 (216–318) 8·6 (7·2–10·5) 37·3 (30·5–46·4) 1·2 (1·0–1·5) 4·25 (3·55–5·21) 0·1 (0·1–0·2)
Other pharynx cancer 245 (211–276) 8·1 (7·0–9·1) 7·10 (6·26–7·92) 0·2 (0·2–0·3) 4·36 (3·76–4·91) 0·1 (0·1–0·2)
Kidney cancer 239 (220–264) 7·9 (7·3–8·8) 21·1 (19·3–23·3) 0·7 (0·6–0·8) 4·02 (3·69–4·43) 0·1 (0·1–0·1)
Thyroid cancer 191 (168–214) 6·4 (5·6–7·1) 46·8 (40·6–51·7) 1·6 (1·3–1·7) 2·85 (2·52–3·17) 0·1 (0·1–0·1)
Gallbladder and biliary tract cancer 133 (113–147) 4·4 (3·7–4·9) 3·84 (3·29–4·26) 0·1 (0·1–0·1) 2·39 (2·03–2·66) 0·1 (0·1–0·1)
Larynx cancer 128 (118–140) 4·2 (3·9–4·6) 4·21 (3·88–4·58) 0·1 (0·1–0·2) 2·25 (2·06–2·47) 0·1 (0·1–0·1)
Bladder cancer 124 (113–137) 4·1 (3·7–4·5) 14·1 (12·6–15·8) 0·5 (0·4–0·5) 2·05 (1·85–2·28) 0·1 (0·1–0·1)
Uterine cancer 110 (85·1–124) 3·6 (2·8–4·1) 19·4 (15·8–22·0) 0·6 (0·5–0·7) 1·81 (1·39–2·04) 0·1 (0·0–0·1)
Multiple myeloma 95·6 (74·3–107) 3·2 (2·5–3·5) 2·93 (2·26–3·34) 0·1 (0·1–0·1) 1·68 (1·31–1·88) 0·1 (0·0–0·1)
Chronic lymphoid leukaemia 61·4 (52·8–69·4) 2·0 (1·8–2·3) 4·26 (3·65–4·88) 0·1 (0·1–0·2) 1·01 (0·872–1·14) 0·0 (0·0–0·0)
Mesothelioma 56·4 (44·1–67·9) 1·9 (1·5–2·2) 1·47 (1·15–1·79) 0·0 (0·0–0·1) 0·990 (0·777–1·20) 0·0 (0·0–0·0)
Prostate cancer 54·3 (47·2–66·1) 1·8 (1·6–2·2) 5·47 (4·78–6·55) 0·2 (0·2–0·2) 0·876 (0·757–1·06) 0·0 (0·0–0·0)
Other malignant neoplasms 3230 (2920–3530) 109·1 (98·8–119·4) 141 (130–154) 4·8 (4·4–5·2) 51·5 (46·6–56·2) 1·7 (1·6–1·9)
Estimates are for individuals aged 15–39 years, both sexes combined. Values in parentheses are 95% uncertainty intervals (UIs). Rates are reported per 100 000 person-years. Cancer types are listed in order of 
global DALY burden, with the exception of “other malignant neoplasms”, which are listed last. Other malignant neoplasms are cancers without a detailed GBD cause separately listed. Other leukaemia included 
leukaemias not otherwise specified. Non-melanoma skin cancers were not included in this analysis. SDI categories do not sum precisely to the global total as GBD 2019 does not provide separate estimates for all 
locations globally and an adjustment factor is made between all estimated locations, which have corresponding SDI values, and the global estimate. DALYs=disability-adjusted life years. UI=uncertainty interval. 
GBD=Global Burden of Diseases, Injuries, and Risk Factors Study. SDI=Socio-demographic Index.
Table: Adolescent and young adult cancer burden globally and by SDI quintile in 2019
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from diagnosis, two phases were estimated for the 
10­year time period after diagnosis: diagnosis or 
treatment; and remission. After the 10­year period, the 
disability risk was returned to the baseline of the general 
population without a cancer diagnosis. For cohorts that 
did not survive beyond 10 years from diagnosis, 
two additional phases were estimated: the metastatic or 
disseminated phase; and the terminal phase. YLD 
estimates were generated by multiplying each phase 
prevalence by a phase­specific disability weight, repre­
sentative of the health loss magnitude associated with 
a specified health outcome. Disability weights are 
measured on a scale of 0 (full health) to 1 (equivalent to 
death; appendix p 55). YLLs were calculated as the 
standard life expectancy at the age of death multiplied by 
age­specific cancer deaths.14 DALY estimates were the 
sum of the YLD and YLL estimates. Proportional DALYs 
for each cancer cause and 5­year age group were 
calculated as the mean of 1000 proportion draws of the 
absolute number of DALYs for each cancer cause and age 
group divided by the total number of cancer DALYs 
within the same age group. Proportional DALYs for each 
SDI were calculated as the mean of 1000 proportion 
draws of the absolute number of DALYs for each cancer 
cause within each SDI quintile and divided by the total 
number of DALYs in each SDI quintile (appendix p 56). 
An additional analysis was done to identify the proportion 
of adolescent and young adult cancer cases covered by 
the WHO Global Initiative for Childhood Cancer 
(appendix p 56). Further detailed descriptions of the 
methods are provided in the appendix (pp 7–57) and in 
GBD 2019 summary publications.13,14
Uncertainty analysis
Final point estimates are reported with 95% uncertainty 
intervals (UIs). 95% UIs are 95% ranges calculated as the 
range from the 2·5th to the 97·5th percentile on the 
basis of the distribution of 1000 draws at each GBD 
cancer estimation step, with uncertainty propagated 
through each step (appendix p 57).
Role of the funding source
The funders of this study had no role in the design of the 
GBD cancer estimation process, collection or analysis of 
data, interpretation of results, or in the writing of this 
manuscript.
Results
There were an estimated 1·19 million (95% UI 1·11–1·28) 
incident cancer cases and 396 000 (370 000–425 000) 
deaths among individuals aged 15–39 years worldwide in 
2019 (table). The highest age­standardised incidence rates 
were seen in high SDI (59·6 [54·5–65·7] per 
100 000 person­years) and high­middle SDI (53·2 
[48·8–57·9] per 100 000 person­years) countries, while the 
highest age­standardised mortality rates from cancer in 
adolescents and young adults were seen in middle 
SDI (13·6 [12·6–14·8] per 100 000 person­years) and 
low­middle SDI (14·2 [12·9–15·6] per 100 000 person­
years) regions. Adolescent and young adult cancers 
contributed 23·5 million (21·9–25·2) DALYs to the global 
burden of disease in 2019 (table), of which 2·7% (1·9–3·6) 
came from YLDs and 97·3% (96·4–98·1) from YLLs 
(appendix p 79). The majority (91·4% [91·0–91·8]) of the 
worldwide absolute adolescent and young adult cancer 
DALY burden is concentrated in non­high SDI (low, low­
middle, middle, and high­middle SDI) quintiles. Overall, 
high SDI settings have the highest age­standardised 
incidence rate (59·6 [54·5–65·7] per 100 000 person­
years), but the lowest age­standardised DALY rate (564·3 
[542·8–590·1] per 100 000 person­years). Breast cancer 
(10·6% [10·0–11·2]), followed by brain and CNS cancer 
(7·4% [6·0–8·0]), colon and rectum cancer (7·0% 
[6·6–7·3]), and stomach cancer (6·7% [6·5–7·0]) were the 
four greatest contributors to the DALY burden globally 
for both sexes combined, of separately categorised cancers 
(appendix p 81). If leukaemias were considered as a single 
group, given that they are treated by haematologist­
oncologists and have a similar diagnostic approach, 
rather than as individual leukaemia subtypes, leukaemias 
would be the largest categorised cancer group contributing 
to the global cancer DALY burden (12·0% [10·9–12·8]), 
greater than that of breast cancer. The “other malignant 
neoplasms” category, the aggregated cancer cause 
category for cancers not separately estimated in the GBD 
framework, comprised the highest proportion of the 
adolescent and young adult cancer DALY burden globally 
(13·7% [12·8–14·5]; appendix p 81). A focused analysis of 
individuals aged 15–29 years is provided in the appendix 
(pp 115–122).
The greatest burden of cancer in adolescents and 
young adults in 2019, as represented by age­standardised 
DALY rates, was concentrated in parts of Asia, southern 
sub­Saharan Africa, and South America (figure 1A; 
appendix p 84). The distribution of DALYs due to cancer 
in adolescents and young adults is distinct from that of 
children (figure 1B) and older adults (figure 1C). The 
geographical pattern of age­standardised DALY rate 
quintiles for adolescent and young adult cancer was 
similar to the geographical pattern of childhood cancers 
in high SDI countries and resembled the distribution of 
adult cancer in low and middle SDI countries (figure 1).
Of all age groups, individuals aged 35–39 years had 
the largest contribution to the adolescent and young 
adult global cancer DALYs (8·4 million [95% UI 
7·8–9·0], with corresponding DALY rates of 1547·6 
[1441·3–1658·0] per 100 000 person­years; figure 2A). 
The proportion of DALYs attributed to leukaemias 
declined with increasing age across the adolescent and 
young adult population (26·7% [24·8–28·8] of total 
age group DALYs, corresponding to 0·64 million 
[0·56–0·72] DALYs in those aged 15–19 years vs 6·2% 
[5·6–6·7] of total age group DALYs, corresponding 
to 0·52 million [0·46–0·58] DALYs in those aged 
For more on the WHO Global 
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35–39 years; appendix p 107). The proportion of DALYs 
attributed to carcinomas increased with increasing age 
across the adolescent and young adult population 
(18·1% [17·3–19·3] of total age group DALYs in those 
aged 15–19 years, corresponding to 0·43 million 
[0·40–0·47] DALYs vs 73·6% [72·7–75·2] of total age 
group DALYs, corresponding to 6·2 million [5·7–6·6] 
DALYs in those aged 35–39 years; figure 2B; appendix 
p 107). There was a notable proportion of “other 
malignant neoplasms” across the adolescent and young 
adult population, which was highest in those aged 
15–19 years (30·6% [28·6–32·2] of total age group 
DALYs, corresponding to 0·73 million [0·65–0·81] 
DALYs), and lowest in those aged 35–39 years (7·1% 
[6·5–7·5] of total age group DALYs, corresponding to 
0·59 million [0·54–0·65] DALYs; figure 2B). In direct 
comparisons of the proportional DALY burden for the 
15–29­year age group with that of the 30–39­year age 
group, there is a transition in the predominant cause 
from leukaemias and lymphomas to carcinomas, 
especially breast and cervical cancer (appendix p 122).
When assessed by SDI quintile, age­standardised 
DALY rates and the proportional DALY burden varied by 
cancer type (figure 3). Individuals in the high SDI 
quintile had a lower age­standardised DALY rate (564·3 
[95% UI 542·8–590·1] DALYs per 100 000 person­years; 
figure 3A) than other SDI quintiles. Estimates of the 
proportion of the DALY burden due to cervical cancer 
increased with decreasing SDI quintile, having the 
lowest proportional burden in the high SDI setting (4·1% 
[3·7–4·4]; figure 3B) and the highest burden in the low 
SDI setting (12·1% [10·4–14·4]; figure 3B). The adolescent 
and young adult cancer burden attributed to brain and 
CNS cancer was highest in the high SDI (10·7% 
[8·8–11·6]) and high­middle SDI (9·0% [7·2–9·7]) 
quintiles, compared to the low­middle SDI (6·1% 
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Figure 1: Global map of age-standardised DALY rates for both sexes combined in 2019, categorised by age-standardised DALY rate quintiles, excluding non-melanoma skin cancers, 
for malignant adolescent and young adult cancers (A), malignant childhood cancers (B), and malignant adult cancers (C)
Quintiles are based on age-standardised DALY rates per 100 000 person-years. For adolescent and young adult cancers (age 15–39 years), quintile 1 (0–20%) corresponds to less than 597 DALYs per 
100 000 person-years, quintile 2 (21–40%) corresponds to 597 to less than 729 DALYs per 100 000 person-years, quintile 3 (41–60%) corresponds to 729 to less than 833 DALYs per 
100 000 person-years, quintile 4 (61–80%) corresponds to 833 to less than 1010 DALYs per 100 000 person-years, and quintile 5 (81–100%) corresponds to 1010 or more DALYs per 
100 000 person-years. For childhood cancers (age 0–14 years), quintile 1 (0–20%) corresponds to less than 250 DALYs per 100 000 person-years, quintile 2 (21–40%) corresponds to 250 to less than 
311 DALYs per 100 000 person-years, quintile 3 (41–60%) corresponds to 311 to less than 396 DALYs per 100 000 person-years, quintile 4 (61–80%) corresponds to 396 to less than 495 DALYs per 
100 000 person-years, and quintile 5 (81–100%) corresponds to 495 or more DALYs per 100 000 person-years. For adult cancers (age ≥40 years), quintile 1 (0–20%) corresponds to less than 
6680 DALYs per 100 000 person-years, quintile 2 (21–40%) corresponds to 6680 to less than 7390 DALYs per 100 000 person-years, quintile 3 (41–60%) corresponds to 7390 to less than 8580 DALYs 
per 100 000 person-years, quintile 4 (61–80%) corresponds to 8580 to less than 9890 DALYs per 100 000 person-years, and quintile 5 (81–100%) corresponds to 9890 or more DALYs per 
100 000 person-years. There are several geographical locations (shown in white) where estimates are not available (eg, Western Sahara and French Guiana) as they were not modelled locations in GBD 
2019. DALY=disability-adjusted life-year. GBD=Global Burden of Diseases, Injuries, and Risk Factors Study.
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[5·0–6·9]) and low SDI (5·2% [4·0–6·2]) quintiles. The 
proportion of adolescent and young adult cancers that 
were in the “other malignant neoplasms” category was 
highest in the low SDI quintile (20·1% [18·7–22·2]) and 
lowest in the high­middle SDI quintile (9·9% [9·5–10·6]).
The top five causes by absolute DALY burden in 
females globally in 2019 were breast cancer (2·46 million 
[95% UI 2·23–2·70] DALYs), cervical cancer (1·56 million 
[1·32–1·78] DALYs), “other malignant neoplasms” 
(1·35 million [1·21–1·51] DALYs), stomach cancer 
(732 000 [653 000–814 000] DALYs), and brain and CNS 
cancer (722 000 [536 000–827 000] DALYs; figure 4; 
appendix pp 66–69). The five cancers with the highest 
absolute DALY burden in males were “other malignant 
neoplasms” (1·88 million [1·64–2·12] DALYs); brain 
and CNS cancer (1·03 million [0·76–1·19] DALYs); 
colon and rectum cancer (973 000 [887 000–1 070 000] 
DALYs); tracheal, bronchus, and lung cancer (856 000 
[766 000–952 000] DALYs); and stomach cancer (842 000 
[767 000–928 000] DALYs; figure 4; appendix pp 62–65). In 
2019, females had a higher overall incidence of cancer 
than males globally (686 000 [622 000–751 000] vs 509 000 
[469 000–549 000] incident cancer cases), but had similar 
absolute mortality (202 000 [184 000–222 000] vs 194 000 
[179 000–209 000] deaths; appendix pp 62, 66, 82–83). 
Breast and cervical cancer combined made up a 
substantial proportion of the DALY burden globally in 
females (33·6% [32·3–35·1]). Among the non­sex­specific 
cancer causes, males had higher absolute DALYs globally 
in 24 of 27 cancer groups, representing a 13·7% 
(3·5–25·1) overall higher absolute number of DALYs 
than females.
Rankings of the burden of absolute DALYs and deaths 
due to adolescent and young adult cancer compared to 
other diseases in individuals aged 15–39 years, both 
globally and by SDI quintile, are shown in figure 5. 
Adolescent and young adult cancer had the tenth highest 
DALY burden globally (23·5 million [95% UI 21·9–25·2] 
DALYs; figure 5A) among 22 causes of DALYs at this level 
in the GBD hierarchy. The inter­category rankings show 
that cancer ranks higher than other prominent causes of 
DALYs in high, high­middle, and middle SDI quintiles, 
compared to low­middle and low SDI quintiles. In 
adolescents and young adults, deaths from cancer ranked 
fourth globally (396 000 [370 000–425 000]; figure 5B), 
among 21 causes of death at this level in the GBD 
hierarchy, with a higher intra­SDI­quintile ranking in 
high, high­middle, and middle SDI regions, compared to 
low­middle and low SDI regions. In comparison, deaths 
due to cancer ranked 11th globally in those younger than 
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Figure 2: Global age-specific DALY rates (A) and proportional DALY burden (B) of adolescent and young adult cancer types by age group, in 2019, for both 
sexes combined
Rates are expressed per 100 000 person-years. “Other malignant neoplasms” comprise all malignancies without a separate GBD cause category listed; this category does 
not include non-melanoma skin cancers and myelodysplastic or myeloproliferative neoplasms, which are separate GBD cause categories not included in this analysis. 
Other leukaemia included leukaemias not otherwise specified. DALY=disability-adjusted life-year. GBD=Global Burden of Diseases, Injuries, and Risk Factors Study.
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15 years and second in those older than 39 years 
(appendix pp 105, 106). In 2019, deaths due to cancer in 
the adolescent and young adult population were lower 
than those estimated for transport injuries and cardio­
vascular and circulatory diseases, but higher than those 
estimated for HIV/AIDS and sexually transmitted 
infections, respiratory infections and tuberculosis, and 
unintentional injuries (figure 5B). More detailed findings 
are summarised in the appendix (pp 62–114). An 
additional analysis showed that 8·6% (95% UI 8·2–9·1) 
of all adolescent and young adult cancer cases are 
included in the WHO Global Initiative for Childhood 
Cancer (appendix p 56).
Discussion
In our analysis of adolescent and young adult cancer, 
based on data from GBD 2019, we show, to the best of our 
knowledge, for the first time that the global burden of 
adolescent and young adult cancer is substantial in terms 
of DALYs, a measure that is frequently used by govern­
ments to inform policy and resource allocation needs. 
From a descriptive perspective, the age­standardised 
distribution of adolescent and young adult DALYs was 
unique compared to both childhood and adult cancers, 
reflecting an expected but ill­described transition from 
childhood to adult cancer epidemiological patterns.20–22 
Additionally, when the overall disease burden is studied 
cross­sectionally within the age range encompassing 
adolescents and young adults, the global burden of cancer 
contributed more DALYs to the global disease burden 
than some high­profile communicable diseases such as 
HIV/AIDS and sexually transmitted infections. This 
comparison of cancer with other leading causes of global 
mortality and DALYs in adolescents and young adults has 
not been previously documented. These results highlight 
that cancer is an important contributor to premature 
death and the disease burden in adolescents and young 
adults globally, even when compared with some com­
municable diseases that that are the focus of more active 
global funding, research, and advocacy efforts.1,23 The 
findings also underscore the need to develop a global 
strategy to address the cancer burden in this population, 
which should include the integration of adolescent and 
young adult cancer into overall cancer control planning 
and universal health coverage plans.24
Because of the substantial burden of adolescent and 
young adult cancers globally, with the majority of DALYs 
occurring on the lower end of the SDI spectrum, broader 
Cancer type
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Figure 3: Age-standardised DALY rates (A) and proportional adolescent and young adult cancer DALY burden (B) by Socio-demographic Index, in 2019, 
for both sexes combined
Rates are expressed per 100 000 person-years. “Other malignant neoplasms” comprise all malignancies without a separate GBD cause category listed; this category 
does not include non-melanoma skin cancers and myelodysplastic or myeloproliferative neoplasms, which are separate GBD cause categories not included in this 
analysis. Other leukaemia included leukaemias not otherwise specified. DALY=disability-adjusted life-year. GBD=Global Burden of Diseases, Injuries, and Risk Factors 
Study. SDI=Socio-demographic Index.
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attention to the unique determinants driving cancer 
outcomes in this age range is needed.5 In 2017, the World 
Health Assembly accepted the global cancer challenge 
resolution, which stated the importance of including 
children and adolescents in the development of cancer 
control programmes.8 The World Health Assembly noted 
in particular that these populations often experience 
delays and difficulties in accessing care. Unfortunately, 
the resolution did not address the unique needs of young 
adults separately, thus reinforcing a gap in current global 
cancer control paradigms. There is an opportunity 
for advocates to directly address this gap, petitioning 
member states and developing an amend ment specific to 
adolescents and young adults by emphasising the 
barriers faced by these patients.
The psychosocial challenges adolescents and young 
adults face is an important issue since these challenges 
are truly unique across the age spectrum and require 
resources and skills that are often not available to cancer 
treatment teams.25 The age range of adolescents and 
young adults encompasses their formative years in life 
and spans the time from completing education, to 
possibly starting a career and raising children, and 
potentially contributing to society more broadly. A cancer 
diagnosis during these years can have a considerable 
impact on individuals’ future life trajectory through 
major stressors, including feelings of isolation, anxiety 
and depression, concerns about infertility, discontinuing 
schooling or work, and financial hardship.1,12,26–28 Efforts to 
mitigate the issues distinct to this age group have 
resulted in the formation of organisations to help support 
adolescent and young adult patients with cancer. 
However, although these oncology advocacy efforts 
focused on adolescents and young adults have been 
successful in creating awareness campaigns and 
implementing adolescent and young adult programmes 
at cancer centres, these efforts have largely been limited 
to high­income countries.29 These initiatives need to be 
expanded globally, particularly in low SDI settings—
which carry a disproportionate burden of adolescent and 
young adult cancer DALYs—with appropriate local 
knowledge and champions.
The array of cancer types is also unique in adolescents 
and young adults compared to children and adults. Even 
what seems to be the same cancer is often biologically 
different in adolescents and young adults than in patients 
of other age groups and thereby might benefit from a 
different approach to therapy.6 For these and other 
reasons, survival improvements in adolescent and young 
adult patients with cancer have lagged behind those of 
children and adults for several cancer types.9 Delivery of 
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Figure 4: Global absolute (A) and proportional (B) adolescent and young adult cancer DALY burden by sex in 2019
Other malignant neoplasms comprise all malignancies without a separate GBD cause category listed; this category does not include non-melanoma skin cancers and 
myelodysplastic or myeloproliferative neoplasms, which are separate GBD cause categories not included in this analysis. Other leukaemia included leukaemias not 
otherwise specified. DALY=disability-adjusted life-year. GBD=Global Burden of Diseases, Injuries, and Risk Factors Study.
Articles
www.thelancet.com/oncology   Published online December 3, 2021   https://doi.org/10.1016/S1470-2045(21)00581-7 11
 Absolute DALYs, 
millions (95% UI) 








Low SDI rank 
Mental disorders 56·5 (41·0–74·8) 
Self-harm and interpersonal violence 40·5 (37·8–43·4) 
Musculoskeletal disorders 39·4 (27·3–52·6) 
Other non-communicable diseases 37·5 (27·3–51·8) 
Transport injuries 35·7 (32·1–38·7) 
Neurological disorders 30·5 (10·8–60·4) 
Cardiovascular diseases 29·8 (27·6–32·1) 
Unintentional injuries 29·7 (25·9–34·3) 
Respiratory infections and tuberculosis 24·3 (21·6–27·1) 
Adolescent and young adult cancers 23·5 (21·9–25·2) 
HIV/AIDS and sexually transmitted infections 23·3 (18·3–30·4) 
Substance use disorders 19·8 (15·3–25·0) 
Digestive diseases 19·3 (17·1–22·1) 
Maternal and neonatal disorders 18·4 (16·3–20·6) 
Skin and subcutaneous diseases 15·5 (10·1–23·1) 
Diabetes and kidney diseases 13·2 (11·4–15·2) 
Enteric infections 12·0 (8·74–16·5) 
Neglected tropical diseases and malaria 10·8 (7·65–14·6) 
Nutritional deficiencies 10·3 (6·95–14·5) 
Sense organ diseases 10·1 (6·52–14·8) 
Chronic respiratory diseases 9·04 (7·59–10·8) 





































































































































Self-harm and interpersonal violence 599 000 (559 000–641 000) 
Transport injuries 505 000 (451 000–550 000) 
Cardiovascular diseases 456 000 (420 000–494 000) 
Adolescent and young adult cancers 396 000 (370 000–425 000)  
HIV/AIDS and sexually transmitted infections 357 000 (271 000–480 000) 
Respiratory infections and tuberculosis 321 000 (292 000–354 000) 
Unintentional injuries 321 000 (285 000–351 000)  
Digestive diseases 245 000 (224 000–267 000) 
Maternal and neonatal disorders 161 000 (140 000–184 000) 
Enteric infections 140 000 (93 600–207 000) 
Diabetes and kidney diseases 127 000 (117 000–138 000) 
Substance use disorders 95 100 (88 300–102 000) 
Neglected tropical diseases and malaria 93 600 (54 000–152 000) 
Other infectious diseases 87 600 (78 400–98 700) 
Other non-communicable diseases 82 800 (74 100–92 900) 
Chronic respiratory diseases 58 000 (52 500–64 100) 
Neurological disorders 51 700 (47 100–57 700) 
Nutritional deficiencies 12 200 (10 500–14 200) 
Musculoskeletal disorders 11 100 (9000–13 300) 
Skin and subcutaneous diseases 4940 (3450–5740) 
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A
B
Figure 5: Ranking of absolute DALYs (A) and deaths (B) due to cancer compared to other disease groups in adolescents and young adults in 2019, for both 
sexes combined, globally and by SDI
Disease rank assigned by total absolute DALYs (A) or absolute deaths (B) globally in 2019 in the adolescent and young adult age group (15–39 years), with 
1 representing the highest rank. Values in parentheses are 95% uncertainty intervals (UIs). Colour intensity is proportional to rank number (from 1 denoted by dark 
red to 22 [or 21 in panel B] denoted by dark green). Cancers comprise all malignant neoplasms, excluding non-melanoma skin cancers. Panels A and B included 
different causes because some causes do not have mortality estimated in this age range. Other non-communicable diseases comprise congenital birth defects; urinary 
diseases and male infertility; gynaecological diseases; haemoglobinopathies and haemolytic anaemias; endocrine, metabolic, blood, and immune disorders; and oral 
disorders. Other infectious diseases comprise meningitis, encephalitis, diphtheria, whooping cough, tetanus, measles, varicella and herpes zoster, acute hepatitis, 
and other unspecified infectious diseases. DALY=disability-adjusted life-year. SDI=Socio-demographic Index.
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prioritised and optimised, especially in non­high SDI 
settings, where the majority of DALYs are reported. At 
present, adolescent and young adult patients often do not 
have an obvious health­care home and are frequently 
grouped into adult oncology service programmes because 
of age restrictions in paediatric wards or facilities.12,16,30 
Where a patient receives care has important clinical and 
policy ramifications, as there is evidence of improvement 
in survival outcomes for some cancer types (eg, acute 
lymphoblastic leukaemia) when adolescents and young 
adults are treated according to paediatric protocols, 
which are often complex and might be unavailable in 
adult cancer centres.31,32 Furthermore, treatment by 
specialised adolescent and young adult oncology teams 
has been associated with improved survival of adolescents 
and young adults with cancer in some high­income 
countries, possibly as a result of access to cancer 
expertise, clinical trials, and multidisciplinary care.33 
Although access to these centres and programmes is not 
currently possible in many settings, most adolescent and 
young adult patients with cancer might benefit from a 
multidisciplinary treatment approach involving close 
collaboration between paediatric and medical oncologists.
To improve outcomes in this unique population, a new 
approach to global cancer control in adolescents and 
young adults is required. Faced with similar challenges 
for children and adolescents, the recently launched 
WHO Global Initiative for Childhood Cancer provides 
one implementation framework for addressing gaps in 
access and care. This initiative includes adolescents up to 
19 years of age, bridging the lowest ages included in 
adolescent and young adult oncology, and at least one 
cancer that predominantly occurs in adolescents and 
young adults—Hodgkin lymphoma—is an index cancer 
in this initiative. Although this is excellent news for the 
younger bounds of the adolescent and young adult 
spectrum, the Global Initiative for Childhood Cancer 
initiative covers only 8·6% (95% UI 8·2–9·1) of all 
adolescent and young adult cancer cases, and the unique 
needs of and potential synergies with adolescent and 
young adult cancer care are not specifically addressed. 
A dedicated initiative similar to the Global Initiative for 
Childhood Cancer is unlikely in the near future. 
Therefore, integration of adolescent and young adult 
cancer policies within WHO cancer initiatives such as 
the Global Initiative for Childhood Cancer and the WHO 
Cervical Cancer Elimination Initiative, a cancer that 
comprises approximately 10·0% (8·5–10·9) of adolescent 
and young adult cancer cases globally, could be prioritised 
in the short term. A strategy to integrate specific 
objectives of relevance to the adolescent and young adult 
population in these initiatives would immediately cover 
almost one­fifth of adolescent and young adult cancer 
cases and provide a template for future global cancer 
initiatives. Potential areas for collaboration could include 
inte gration of human papillomavirus (HPV) vaccination 
efforts into the Global Initiative for Childhood Cancer, an 
as­yet untapped opportunity, and inclusion of policies 
specific to adolescent and young adult patients in the 
WHO technical packages, such as provisions for referrals 
and access to expert adolescent and young adult cancer 
care and appropriate treatment regimens, psychosocial 
support, and universal health coverage to reduce financial 
hardship. Intentional collaboration with other WHO 
cancer initiatives could facilitate progress in both areas 
and highlight other potential areas of synergy for 
improving cancer outcomes in adolescents and young 
adults.
The adolescent and young adult cancer burden 
estimates presented in this study also underscore the 
limitations of GBD and possible opportunities to improve 
future assessments of the global adolescent and young 
adult cancer burden.34 The classification of adolescent and 
young adult cancers in this study is based on the GBD 
cancer cause list, which has historically focused on 
cancers occurring in adulthood. As such, GBD 2019 did 
not differentiate some of the most common adolescent 
and young adult cancer types, such as soft tissue sarcomas 
and bone tumours. These cancers contribute to the 
substantial proportion of “other malignant neoplasms” in 
this age range, cancers that do not have their own 
individual GBD cancer causes. Many of the rarer cancers 
that fall into this “other malignant neoplasms” category 
rely on complex multidisciplinary therapy (eg, provided 
by medical, radiation, and surgical oncologists), and 
resource allocation could be improved if their global 
burden was accurately known.5 Future studies should use 
the recently updated recommen dations for classification 
of adolescent and young adult cancers to better 
characterise the cancer burden in this age group and 
minimise the number of cancer types falling into the 
“other malignant neoplasms” category.34 Additionally, the 
quality of the data obtained, especially from low­resource 
settings, might cause challenges due to underestimates 
or miscategorisation of less common cancer types.10 
For instance, there was an observed decrease in the 
proportion of adolescent and young adult cancer DALYs 
due to brain and CNS cancers across the SDI spectrum, 
with the lowest proportion in low SDI settings. As many 
lower SDI countries do not have population­based cancer 
registries or robust referral mechanisms, the data upon 
which these estimates are drawn might be subject 
to underdiagnosis, misdiagnosis, or under­reporting. 
There fore, results in lower SDI settings should be 
interpreted with caution. However, these modelled results 
provide a useful contribution towards determining the 
global burden of adolescent and young adult cancer, 
especially in regions where such data do not exist or are 
scarce. An additional limitation of the present analysis is 
that SDI was applied at the national level, but within­
country socio­economic status can vary greatly. Improving 
global adolescent and young adult cancer burden 
estimates must be rooted in capacity­building efforts that 
consider the local context, to ensure identification of 
For more on the WHO Cervical 
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incident cancer cases and deaths in the adolescent and 
young adult population, as well as expansion of and 
support for population­based cancer registration systems. 
Another potential limitation of the present analysis is the 
current approach to YLD estimation, which accounts for 
only 10 years after cancer diagnosis. Previous studies have 
shown that late effects, such as cardiomyopathy, can 
affect the adolescent and young adult population beyond 
the 10­year cutoff point.25,35 This limits the ability to 
determine the long­term chronic disease burden and 
competing risks for survivors in this population, which 
have the potential to be substantial. Additionally, the 
experience of disability for survivors of childhood cancer 
might be different to that of the general population. Thus, 
GBD 2019 might be underestimating the YLDs and 
DALYs associated with cancer in adolescents and young 
adults, and future efforts might be needed to identify 
ways to account for this limitation. Finally, this study 
focused on estimates from 2019, and thus did not 
incorporate the direct and indirect effects of the COVID­19 
pandemic on the global adolescent and young adult 
cancer burden. This will be an important area of 
consideration in future studies as the data become 
available.
This report of the adolescent and young adult cancer 
burden from GBD 2019 identified a considerable burden 
of DALYs due to cancer in the global adolescent and 
young adult population. The absolute mortality burden 
in adolescents and young adults is highest in non­high 
SDI settings, underscoring the need for a global effort to 
improve outcomes in this population, with collaboration 
at the regional and country levels, as well as between 
governments, institutions, academic societies, and 
patient advocacy and non­profit organisations. Efforts to 
comprehensively estimate the global burden of cancer in 
adolescents and young adults are a crucial first step.10,21 
Adolescent and young adult oncology has historically 
been less prioritised than cancer disciplines in younger 
and older patients. Increased awareness of the burden of 
cancer in this population could lead to targeted 
interventions for improved outcomes.
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